‘White House transparency disputes imperil funds to buy Covid therapeutics’ -Stat News Report
https://www.statnews.com/2022/03/04/white-house-transparency-disputes-imperil-funds-to-buy-covid-therapeutics/
Why Kodiak Sciences Shares Are Plunging Today
Kodiak Sciences Inc (NASDAQ: KOD) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-related macular degeneration.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Regeneron Announced Update on Ongoing Dupixent Chronic Spontaneous Urticaria Phase 3 Program; Dupixent Did Not Reach Statistical Significance in an Interim Analysis; Trial Will Be Stopped Due to Futility
A Phase 3 trial (CUPID STUDY B) evaluating Dupixent® (dupilumab) in patients with chronic spontaneous urticaria (CSU), who were refractory to omalizumab, will stop due to futility based on a pre-specified interim analysis.
Lilly’s Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19
The FDA on Friday authorized Eli Lilly And Co's (NYSE:
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: